突变
硫醚
突变体
化学
单加氧酶
基质(水族馆)
立体化学
物候学
环己酮
亚砜
定点突变
组合化学
钙不动杆菌
生物化学
催化作用
酶
生物
有机化学
不动杆菌
细胞色素P450
基因
生态学
抗生素
作者
Shi‐Miao Ren,Feng Liu,Yinqi Wu,Qi Chen,Zhi‐Jun Zhang,Hui‐Lei Yu,Jian‐He Xu
摘要
Abstract Ac CHMO, a cyclohexanone monooxygenase from Acinetobacter calcoaceticus , is a typical Type I Baeyer–Villiger monooxygenase (BVMO). We previously obtained the Ac CHMO M6 mutant, which oxidizes omeprazole sulfide (OPS) to the chiral sulfoxide drug esomeprazole. To further improve the catalytic efficiency of the Ac CHMO M6 mutant, a focused mutagenesis strategy was adopted at the intersections of the FAD‐binding domain, NADPH‐binding domain, and α ‐helical domain based on structural characteristics of Ac CHMO. By using focused mutagenesis and subsequent global evolution two key residues (L55 and P497) at the intersections of the domains were identified. Mutant of L55Y improved catalytic efficiency significantly, whereas the P497S mutant alleviated substrate inhibition remarkably. Ac CHMO M7 (L55Y/P497S) was obtained by combining the two mutations, which increased the specific activity from 18.5 (M6) to 108 U/g, and an increase in the K i of the substrate OPS from 34 to 265 μM. The results indicate that catalytic performance can be elevated by modification of the sensitive sites at the intersection of the domains of Ac CHMO. The results also provided some insights for the engineering of other Type I BVMOs or other multidomain proteins.
科研通智能强力驱动
Strongly Powered by AbleSci AI